Discovery and identification of PIM-1 kinase inhibitors through a hybrid screening approach
详细信息 查看全文
- 作者：Mingfeng Shao (1)
Yiming Yuan (2)
Kun Yu (1)
Kai Lei (1)
Guonian Zhu (1)
Lijuan Chen (1)
Mingli Xiang (1) - 关键词：PIM ; 1 inhibitor ; Hybrid screening ; Pharmacophore modeling ; Inhibitory activity
- 刊名：Molecular Diversity
- 出版年：2014
- 出版时间：May 2014
- 年：2014
- 卷：18
- 期：2
- 页码：335-344
- 全文大小：885 KB
- 参考文献：1. Tahvanainen J, Kyl盲niemi MK, Kanduri K, Gupta B, L盲hteenm盲ki H, Kallonen T, Rajavuori A, Rasool O, Koskinen PJ, Rao KV (2013) Proviral integration site for Moloney murine leukemia virus (PIM) kinases promote human T helper 1 cell differentiation. J Biol Chem 288:3048鈥?058. doi:10.1074/jbc.M112.361709 CrossRef
2. Saluste G, Albarran MI, Alvarez RM, Rabal O, Ortega MA, Blanco C, Kurz G, Salgado A, Pevarello P, Bischoff JR (2012) Fragment-hopping-based discovery of a novel chemical series of proto-oncogene PIM-1 kinase inhibitors. PloS One 7:e45964. doi:10.1371/journal.pone.0045964 CrossRef
3. Nakano H, Saito N, Parker L, Tada Y, Abe M, Tsuganezawa K, Yokoyama S, Tanaka A, Kojima H, Okabe T (2012) Rational evolution of a novel type of potent and selective proviral integration site in Moloney murine leukemia virus kinase 1 (PIM1) inhibitor from a screening-hit compound. J Med Chem 55:5151鈥?164. doi:10.1021/jm3001289 CrossRef
4. Beharry Z, Mahajan S, Zemskova M, Lin Y-W, Tholanikunnel BG, Xia Z, Smith CD, Kraft AS (2011) The Pim protein kinases regulate energy metabolism and cell growth. Proc Natl Acad Sci 108:528鈥?33. doi:10.1073/pnas.1013214108 CrossRef
5. Nihira K, Ando Y, Yamaguchi T, Kagami Y, Miki Y, Yoshida K (2010) Pim-1 controls NF- $\kappa $ B signalling by stabilizing RelA/p65. Cell Death Differ 17:689鈥?98. doi: 10.1038/cdd.2009.174 CrossRef
6. Magnuson NS, Wang Z, Ding G, Reeves R (2010) Why target PIM1 for cancer diagnosis and treatment? Future Oncol 6:1461鈥?478. doi:10.2217/fon.10.106 CrossRef
7. Pierce AC, Jacobs M, Stuver-Moody C (2008) Docking study yields four novel inhibitors of the protooncogene Pim-1 kinase. J Med Chem 51:1972鈥?975. doi:10.1021/jm701248t CrossRef
8. Kumar A, Mandiyan V, Suzuki Y, Zhang C, Rice J, Tsai J, Artis DR, Ibrahim P, Bremer R (2005) Crystal structures of proto-oncogene kinase Pim1: a target of aberrant somatic hypermutations in diffuse large cell lymphoma. J Mol Biol 348:183鈥?93. doi:10.1016/j.jmb.2005.02.039 CrossRef
9. Wang Z, Bhattacharya N, Weaver M, Petersen K, Meyer M, Gapter L, Magnuson NS (2001) Pim-1: a serine/threonine kinase with a role in cell survival, proliferation, differentiation and tumorigenesis. J Vet Sci 2:167鈥?79
10. Pierre F, Stefan E, N茅dellec A-S, Chevrel M-C, Regan CF, Siddiqui-Jain A, Macalino D, Streiner N, Drygin D, Haddach M (2011) 7-(4 $H$ -1,2,4-triazol-3-yl)benzo[ $c$ ][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity. Bioorg Med Chem Lett 21:6687鈥?692. doi: 10.1016/j.bmcl.2011.09.059 CrossRef
11. Qian KC, Wang L, Hickey ER, Studts J, Barringer K, Peng C, Kronkaitis A, Li J, White A, Mische S (2005) Structural basis of constitutive activity and a unique nucleotide binding mode of human Pim-1 kinase. J Biol Chem 280:6130鈥?137. doi:10.1074/jbc.M409123200
12. Merkel AL, Meggers E, Ocker M (2012) PIM1 kinase as a target for cancer therapy. Expert Opin Investig Drug 21:425鈥?36. doi:10.1517/13543784.2012.668527 CrossRef
13. Theo Cuypers H, Selten G, Quint W, Zijlstra M, Maandag ER, Boelens W, van Wezenbeek P, Melief C, Berns A (1984) Murine leukemia virus-induced T-cell lymphomagenesis: integration of proviruses in a distinct chromosomal region. Cell 37:141鈥?50. doi:10.1016/0092-8674(84)90309-X CrossRef
14. Hoover D, Friedmann M, Reeves R, Magnuson N (1991) Recombinant human pim-1 protein exhibits serine/threonine kinase activity. J Biol Chem 266:14018鈥?4023
15. Shah N, Pang B, Yeoh K-G, Thorn S, Chen CS, Lilly MB, Salto-Tellez M (2008) Potential roles for the PIM1 kinase in human cancer: a molecular and therapeutic appraisal. Eur J Cancer 44:2144鈥?151. doi:10.1016/j.ejca.2008.06.044 CrossRef
16. Warnecke-Eberz U, Bollschweiler E, Drebber U, Metzger R, Baldus SE, H枚lscher AH, M枚nig S (2009) Prognostic impact of protein overexpression of the proto-oncogene PIM-1 in gastric cancer. Anticancer Res 29:4451鈥?455
17. Good AC, Liu J, Hirth B, Asmussen G, Xiang Y, Biemann H-P, Bishop KA, Fremgen T, Fitzgerald M, Gladysheva T (2012) Implications of promiscuous Pim-1 kinase fragment inhibitor hydrophobic interactions for fragment-based drug design. J Med Chem 55:2641鈥?648. doi:10.1021/jm2014698 CrossRef
18. Wang Z, Bhattacharya N, Mixter P, Wei W, Sedivy J, Magnuson N (2002) Phosphorylation of the cell cycle inhibitor p21Cip1/WAF1 by Pim-1 kinase. Biochim Biophys Acta 1593:45鈥?5. doi:10.1016/S0167-4889(02)00347-6 CrossRef
19. Qian K, Wang L, Cywin CL, Farmer BT, Hickey E, Homon C, Jakes S, Kashem MA, Lee G, Leonard S (2009) Hit to lead account of the discovery of a new class of inhibitors of Pim linases and crystallographic studies revealing an unusual kinase binding mode. J Med Chem 52:1814鈥?827. doi:10.1021/jm801242y CrossRef
20. Bachmann M, M枚r枚y T (2005) The serine/threonine kinase Pim-1. Int J Biochem Cell B 37:726鈥?30. doi:10.1016/j.biocel.2004.11.005 CrossRef
21. Kim KT, Baird K, Ahn JY, Meltzer P, Lilly M, Levis M, Small D (2005) Pim-1 is up-regulated by constitutively activated FLT3 and plays a role in FLT3-mediated cell survival. Blood 105:1759鈥?767. doi:10.1182/blood-2004-05-2006 CrossRef
22. Brault L, Gasser C, Bracher F, Huber K, Knapp S, Schwaller J (2010) PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers. Haematologica 95:1004鈥?015. doi:10.3324/haematol.2009.017079 CrossRef
23. Muraski JA, Rota M, Misao Y, Fransioli J, Cottage C, Gude N, Esposito G, Delucchi F, Arcarese M, Alvarez R (2007) Pim-1 regulates cardiomyocyte survival downstream of Akt. Nat Med 13:1467鈥?475. doi:10.1038/nm1671 CrossRef
24. Xia Z, Knaak C, Ma J, Beharry ZM, McInnes C, Wang W, Kraft AS, Smith CD (2009) Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. J Med Chem 52:74鈥?6. doi:10.1021/jm800937p CrossRef
25. Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822鈥?26. doi:10.1038/35090585 CrossRef
26. Valdman A, Fang X, Pang ST, Ekman P, Egevad L (2004) Pim-1 expression in prostatic intraepithelial neoplasia and human prostate cancer. Prostate 60:367鈥?71. doi:10.1002/pros.20064 CrossRef
27. Xu Y, Zhang T, Tang H, Zhang S, Liu M, Ren D, Niu Y (2005) Overexpression of PIM-1 is a potential biomarker in prostate carcinoma. J Surg Oncol 92:326鈥?30. doi:10.1002/jso.20325
28. Cibull T, Jones T, Li L, Eble J, Baldridge LA, Malott S, Luo Y, Cheng L (2006) Overexpression of Pim-1 during progression of prostatic adenocarcinoma. J Clin Pathol 59:285鈥?88. doi:10.1136/jcp.2005.027672 CrossRef
29. Magistroni V, Mologni L, Sanselicio S, Reid JF, Redaelli S, Piazza R, Viltadi M, Bovo G, Strada G, Grasso M (2011) ERG deregulation induces PIM1 over-expression and aneuploidy in prostate epithelial cells. PloS One 6:e28162. doi:10.1371/journal.pone.0028162
30. Yan B, Yau EX, Samanta S, Ong CW, Yong KJ, Ng LK, Bhattacharya B, Lim KH, Soong R, Yeoh KG (2012) Clinical and therapeutic relevance of PIM1 kinase in gastric cancer. Gastric Cancer 15:188鈥?97. doi:10.1007/s10120-011-0097-2 CrossRef
31. Guo S, Mao X, Chen J, Huang B, Jin C, Xu Z, Qiu S (2010) Overexpression of Pim-1 in bladder cancer. J Exp Clin Cancer Res 29:161鈥?67. doi:10.1186/1756-9966-29-161 CrossRef
32. Chiang W-F, Yen C-Y, Lin C-N, Liaw G-A, Chiu C-T, Hsia Y-J, Liu S-Y (2006) Up-regulation of a serine鈥搕hreonine kinase proto-oncogene Pim-1 in oral squamous cell carcinoma. Int J Oral Maxillofac Surg 35:740鈥?45. doi:10.1016/j.ijom.2006.01.027 CrossRef
33. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S (2002) The protein kinase complement of the human genome. Science 298:1912鈥?934. doi:10.1126/science.1075762 CrossRef
34. Jacobs MD, Black J, Futer O, Swenson L, Hare B, Fleming M, Saxena K (2005) Pim-1 ligand-bound structures reveal the mechanism of serine/threonine kinase inhibition by LY294002. J Biol Chem 280:13728鈥?3734. doi:10.1074/jbc.M413155200 CrossRef
35. Ma J, Arnold H, Lilly M, Sears R, Kraft A (2007) Negative regulation of Pim-1 protein kinase levels by the B56 $\beta $ subunit of PP2A. Oncogene 26:5145鈥?153. doi: 10.1038/sj.onc.1210323 CrossRef
36. Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646鈥?74. doi:10.1016/j.cell.2011.02.013 CrossRef
37. Stegmeier F, Warmuth M, Sellers W, Dorsch M (2010) Targeted cancer therapies in the twenty-first century: lessons from imatinib. Clin Pharmacol Ther 87:543鈥?52. doi:10.1038/clpt.2009.297 CrossRef
38. Morwick T (2010) Pim kinase inhibitors: a survey of the patent literature. Expert Opin Ther Pat 20:193鈥?12. doi:10.1517/13543770903496442 CrossRef
39. Grey R, Pierce AC, Bemis GW, Jacobs MD, Moody CS, Jajoo R, Mohal N, Green J (2009) Structure-based design of 3-aryl-6-amino-triazolo [4, 3- $b$ ] pyridazine inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 19:3019鈥?022. doi: 10.1016/j.bmcl.2009.04.061 CrossRef
40. Dakin LA, Block MH, Chen H, Dowling JE, Feng X, Ferguson AD, Green I, Hird AW, Howard T, Keeton EK (2012) Discovery of novel benzylidene-1, 3-thiazolidine-2,4-diones as potent and selective inhibitors of the PIM-1, PIM-2, and PIM-3 protein kinases. Bioorg Med Chem Lett 22:4599鈥?604. doi:10.1016/j.bmcl.2012.05.098 CrossRef
41. Xiang Y, Hirth B, Asmussen G, Biemann H-P, Bishop KA, Good A, Fitzgerald M, Gladysheva T, Jain A, Jancsics K (2011) The discovery of novel benzofuran-2-carboxylic acids as potent Pim-1 inhibitors. Bioorg Med Chem Lett 21:3050鈥?056. doi:10.1016/j.bmcl.2011.03.030 CrossRef
42. Ren JX, Li LL, Zheng RL, Xie HZ, Cao ZX, Feng S, Pan YL, Chen X, Wei YQ, Yang SY (2011) Discovery of novel Pim-1 kinase inhibitors by a hierarchical multistage virtual screening approach based on SVM model, pharmacophore, and molecular docking. J Chem Inf Model 51:1364鈥?375. doi:10.1021/ci100464b CrossRef
43. Sliman F, Blairvacq M, Durieu E, Meijer L, Rodrigo J, Desma毛le D (2010) Identification and structure-activity relationship of 8-hydroxy-quinoline-7-carboxylic acid derivatives as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 20:2801鈥?805. doi:10.1016/j.bmcl.2010.03.061 CrossRef
44. Tao ZF, Hasvold LA, Leverson JD, Han EK, Guan R, Johnson EF, Stoll VS, Stewart KD, Stamper G, Soni N (2009) Discovery of 3 $H$ -benzo [4,5] thieno [3, 2- $d$ ] pyrimidin-4-ones as potent, highly selective, and orally bioavailable inhibitors of the human protooncogene proviral insertion site in Moloney murine leukemia virus (PIM) kinases. J Med Chem 52:6621鈥?636. doi: 10.1021/jm900943h CrossRef
45. Jorgensen WL (2004) The many roles of computation in drug discovery. Science 303:1813鈥?818. doi:10.1126/science.1096361 CrossRef
46. Alonso H, Bliznyuk AA, Gready JE (2006) Combining docking and molecular dynamic simulations in drug design. Med Res Rev 26:531鈥?68. doi:10.1002/med.20067 CrossRef
47. Shaikh SA, Jain T, Sandhu G, Latha N, Jayaram B (2007) From drug target to leads-sketching a physicochemical pathway for lead molecule design in silico. Curr Pharm Des 13:3454鈥?470. doi:10.2174/138161207782794220 CrossRef
48. Shekhar C (2008) In silico pharmacology: computer-aided methods could transform drug development. Chem Biol 15:413鈥?14. doi:10.1016/j.chembiol.2008.05.001 CrossRef
49. Kitchen DB, Decornez H, Furr JR, Bajorath J (2004) Docking and scoring in virtual screening for drug discovery: methods and applications. Nat Rev Drug Discov 3:935鈥?49. doi:10.1038/nrd1549
50. Leach AR, Gillet VJ, Lewis RA, Taylor R (2010) Three-dimensional pharmacophore methods in drug discovery. J Med Chem 53:539鈥?58. doi:10.1021/jm900817u CrossRef
51. Lengauer T, Lemmen C, Rarey M, Zimmermann M (2004) Novel technologies for virtual screening. Drug Discov Today 9:27鈥?4. doi:10.1016/S1359-6446(04)02939-3 CrossRef
52. Schneider G, B枚hm H-J (2002) Virtual screening and fast automated docking methods. Drug Discov Today 7:64鈥?0. doi:10.1016/S1359-6446(01)02091-8 CrossRef
53. Gopalakrishnan B, Aparna V, Jeevan J, Ravi M, Desiraju G (2005) A virtual screening approach for thymidine monophosphate kinase inhibitors as antitubercular agents based on docking and pharmacophore models. J Chem Inf Model 45:1101鈥?108. doi:10.1021/ci050064z CrossRef
54. OpenEye Scientific Software Inc. (2012) FRED program. Version 2.2.5 edn. OpenEye Scientific Software Inc., Santa Fe. http://www.eyesopen.com
55. Khan KM, Saied S, Mughal UR, Munawar M, Perveen S (2009) Synthesis, leishmanicidal and enzyme inhibitory activities of quinoline-4-carboxylic acids. J Chem Soc Pak 31:809鈥?18
56. Khan KM, Saify ZS, Khan ZA, Ahmed M, Saeed M, Schick M, Kohlbau H-J, Voelter W (2000) Syntheses and cytotoxic, antimicrobial, antifungal and cardiovascular activity of new quinoline derivatives. Arzneim Forsch Drug Res 50:915鈥?24. doi:10.1055/s-0031-1300313
57. Dror O, Shulman-Peleg A, Nussinov R, Wolfson HJ (2004) Predicting molecular interactions in silico: I. A guide to pharmacophore identification and its applications to drug design. Curr Med Chem 11:71鈥?0. doi:10.2174/0929867043456287 CrossRef
58. Ganellin C, Lindberg P, Mitscher L (1998) Glossary of terms used in medicinal chemistry. Pure Appl Chem 70:1129鈥?143
59. Guner OF (2002) History and evolution of the pharmacophore concept in computer-aided drug design. Curr Top Med Chem 2:1321鈥?332. doi:10.2174/1568026023392940 CrossRef
60. Liao C, Sitzmann M, Pugliese A, Nicklaus MC (2011) Software and resources for computational medicinal chemistry. Future Med Chem 3:1057鈥?085. doi:10.4155/fmc.11.63 CrossRef
61. Accelrys Software Inc. (2012) Discovery studio modeling environment. Release 3.1 edn. Accelrys Software Inc., San Diego
62. McGann MR, Almond HR, Nicholls A, Grant JA, Brown FK (2003) Gaussian docking functions. Biopolymers 68:76鈥?0 CrossRef
63. Eldridge MD, Murray CW, Auton TR, Paolini GV, Mee RP (1997) Empirical scoring functions: I. The development of a fast empirical scoring function to estimate the binding affinity of ligands in receptor complexes. J Comput Aided Mol Des 11:425鈥?45. doi:10.1023/A:1007996124545 CrossRef
64. Verkhivker GM, Bouzida D, Gehlhaar DK, Rejto PA, Arthurs S, Colson AB, Freer ST, Larson V, Luty BA, Marrone T (2000) Deciphering common failures in molecular docking of ligand鈥損rotein complexes. J Comput Aided Mol Des 14:731鈥?51. doi:10.1023/A:1008158231558 CrossRef
65. Stahl M, Rarey M (2001) Detailed analysis of scoring functions for virtual screening. J Med Chem 44:1035鈥?042. doi:10.1021/jm0003992 CrossRef
66. Grant JA, Pickup BT, Nicholls A (2001) A smooth permittivity function for Poisson鈥揃oltzmann solvation methods. J Comput Chem 22:608鈥?40. doi:10.1002/jcc.1032 CrossRef
67. Cheney IW, Yan S, Appleby T, Walker H, Vo T, Yao N, Hamatake R, Hong Z, Wu JZ (2007) Identification and structure鈥揳ctivity relationships of substituted pyridones as inhibitors of Pim-1 kinase. Bioorg Med Chem Lett 17:1679鈥?683. doi:10.1016/j.bmcl.2006.12.086
68. Bostrom J (2001) Reproducing the conformations of protein-bound ligands: a critical evaluation of several popular conformational searching tools. J Comput Aided Mol Des 15:1137鈥?152. doi:10.1023/A:1015930826903
69. ChemAxon Ltd. (2011) MarvinSketch, 5.6.0.1 edn. ChemAxon Ltd., Budapest. http://www.chemaxon.com
70. Halgren TA (1996) Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94. J Comput Chem 17:490鈥?19. doi:10.1002/(SICI)1096-987X(199604)17:5/6<490::AID-JCC1>3.0.CO;2-P
71. K-j Wu, Zeng J, Zhu G-d, Zhang L-l, Zhang D, Li L, Fan J-h, Wang X-y, He D-l (2009) Silibinin inhibits prostate cancer invasion, motility and migration by suppressing vimentin and MMP-2 expression. Acta Pharmacol Sin 30:1162鈥?168. doi:10.1038/aps.2009.94 CrossRef - 作者单位：Mingfeng Shao (1)
Yiming Yuan (2)
Kun Yu (1)
Kai Lei (1)
Guonian Zhu (1)
Lijuan Chen (1)
Mingli Xiang (1)
1. State Key Laboratory of Biotherapy, West China Hospital, West China Medical School, Sichuan University, # 1 Keyuan Road 4, Gaopeng Street, High Technological Development Zone, Chengdu聽, 610041, China
2. Department of Geriatric Medicine, West China Hospital, West China Medical School, Sichuan University, # 17, Section 3, Ren Min Nan Lu, Chengdu聽, 610041, China - ISSN：1573-501X
文摘
PIM-1 kinase is an important therapeutic target in the treatment of cancer. Discovery and identification of PIM-1 Inhibitors with novel scaffolds are an effective way for developing potent therapeutic agents for the treatment of cancers. Here we proposed a hybrid screening approach which combines an optimal structure-based drug design strategy and a simple pharmacophore model to discover PIM-1 kinase inhibitors. With the proposed hybrid screening approach, the SPECS database containing 204,580 molecules was screened. In total, 89 hits were obtained. Forty three of them were purchased and tested in bioassays. Finally, 5 lead compounds with novel scaffolds were identified to exhibit promising antitumor activities against human leukemia cell line MV4-11, K-562 and human prostate cancer cell line PC-3 and DU145. Their $\hbox {IC}_{50}$ values range from 4.40 to $37.96 \,\upmu \hbox {M}$ . Three hits with 3 different scaffolds were selected from these five hits for binding mode analysis. It was demonstrated that the subtle differences in the interactions of the representatives with PIM-1 kinase contribute to the different inhibitory activities. It was also demonstrated that the suggested hybrid screening approach is an effective method to discover PIM-1 inhibitors possessing different scaffolds. These leads have a strong likelihood to act as further starting points for us in the optimization and development of potent PIM-1 inhibitors.